Physician profile
Rizza P Ray
NPI 1780752238
$2,555.62
in general payments reported to CMS, 2019-2025
21 companies · $703 in 2025
The $703 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $259 · 2023: $758 · 2024: $836 · 2025: $703.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,297.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,296.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $640.81 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $308.97 | 2022-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $308.66 | 2022-2025 | |
| Amgen INC. | $242.24 | 2022-2025 | Repatha, Repatha |
| Edwards Lifesciences Corporation | $231.22 | 2022-2025 | Sapien 3 Ultra Resilia |
| Abbott Laboratories | $143.01 | 2023-2025 | Aveir, Jot Dx, Gallant |
| Janssen Pharmaceuticals, INC | $86.49 | 2022-2024 | Xarelto |
| Lilly USA, LLC | $84.71 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Merck Sharp & Dohme LLC | $83.58 | 2022-2024 | Verquvo |
| Alnylam Pharmaceuticals INC. | $66.58 | 2023-2024 | Amvuttra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.10 | 2023-2024 | Jardiance |
| Novo Nordisk INC | $52.09 | 2025 | Wegovy |
| Boston Scientific Corporation | $46.85 | 2023 | Watchman Access System |
| Ionis Pharmaceuticals, INC. | $45.25 | 2025 | Tryngolza |
| Kiniksa Pharmaceuticals International, Plc | $41.62 | 2024 | Arcalyst |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $32.05 | 2023 | Inpefa |
| Scpharmaceuticals INC. | $22.32 | 2023 | |
| Kiniksa Pharmaceuticals, LTD. | $19.80 | 2023 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $18.80 | 2024 | Farxiga |
| Regeneron Healthcare Solutions, INC. | $15.51 | 2023 | Evkeeza |
| Bayer Healthcare Pharmaceuticals INC. | $12.96 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rizza Ray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.